6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease.
about
Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel diseaseRac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine TherapyInfluence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.Pharmacogenomics of IBD TherapiesUse of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications.Novel strategies in the thiopurine treatment of inflammatory bowel disease.Thiopurine therapy in inflammatory bowel disease.Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus.The role and advances of immunomodulator therapy for inflammatory bowel disease.Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4.Drug Management in the Elderly IBD Patient.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.Toxicity and response to thiopurines in patients with inflammatory bowel disease.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy?How should thiopurine treatment be monitored?--methodological aspects.Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease.Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease.Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.Thiopurine Metabolism in the Era of Combotherapy.Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease.Evaluation of Stability of Thiopurine Metabolites Using a Validated LC-MS/MS Method.Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
P2860
Q24631869-E434FD4C-7A5C-4C94-9581-4518E969E2C9Q28067937-6B9CD018-4216-4443-83AA-2B4AC3C83DACQ34112953-23EB1BF8-324B-48AF-A3B4-D4F2B6B72357Q34996751-5B981905-6323-4E9F-8D7E-F1DC29287709Q37094598-4CD95FEF-04F8-4908-AED1-D6903FE78BADQ37345896-13B9B2A1-28FF-4761-B328-A391887CE0E7Q37764761-53FD973D-6E94-4ACD-BB03-58113D7DEA13Q37798819-98FC828D-5144-483A-BB39-EDF0C9FD444BQ38095599-3BBAC37A-3740-40E6-ABA1-7477F9C96FB9Q38237701-C9AA1A08-2716-4F87-BE68-6EE995340802Q38253469-348FA704-80F9-4A66-B053-BE40935EA301Q38293233-D987A558-F4A9-4289-AD0B-E05B61940E45Q38330651-7AEFF6D2-CCF5-456A-9F50-D8B1C3077B22Q38417177-C0EE8E6F-A6F8-4DE0-9215-BBA1F149C17DQ38443981-760D3BAB-DC80-4EB8-B098-A1DB8F8B99BDQ38563075-AA96F3F1-101F-4E7B-B402-DD1056DC2F81Q42319267-1279AF58-D2DD-428B-923D-4359EB3C71E5Q43026590-E9B8BA57-3935-4B1D-B53F-B4514B37164DQ46124674-6FEB33BA-BEDF-4832-ABED-4C0F393C5E99Q46214775-841619A9-2C5C-4A83-8668-71DDA127E8D1Q47426181-039A3095-F6F2-461E-836F-45A8DA6F4493Q50495588-6C5C8E08-A0F5-40D5-9319-F26CFF04C687Q50691937-DC2E3FB3-9E11-4FB0-AC44-6C848A8EFA09Q50708004-31EDCB2F-936A-4B31-8FDC-C597A6668CE3Q55311673-787B9FEB-6E58-401C-A91A-F5FD20E058C2Q57817595-A74138EF-5732-4827-BBA2-2A73ADB539F6
P2860
6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
6-thioguanosine diphosphate an ...... ne therapy in Crohn's disease.
@en
6-thioguanosine diphosphate an ...... ne therapy in Crohn's disease.
@nl
type
label
6-thioguanosine diphosphate an ...... ne therapy in Crohn's disease.
@en
6-thioguanosine diphosphate an ...... ne therapy in Crohn's disease.
@nl
prefLabel
6-thioguanosine diphosphate an ...... ne therapy in Crohn's disease.
@en
6-thioguanosine diphosphate an ...... ne therapy in Crohn's disease.
@nl
P2093
P1476
6-thioguanosine diphosphate an ...... ne therapy in Crohn's disease.
@en
P2093
Christine Fischer
Markus F Neurath
Matthias Schwab
Michel Eichelbaum
Peter R Galle
Ralf Kiesslich
Ute Teichgräber
P304
P356
10.1016/S1542-3565(05)00697-X
P407
P50
P577
2005-10-01T00:00:00Z